A case report of drug rash with eosinophilia and systemic symptoms syndrome induced by dapsone

Swathy A. R., A. N. Dattatri*

Department of Pharmacology, Karnataka Institute of Medical Science, Hubballi, Karnataka, India

Received: 26 December 2019
Revised: 10 March 2020
Accepted: 11 March 2020

*Correspondence:
Dr. A. N. Dattatri
Email: dattatri69@gmail.com

ABSTRACT

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a distinct, severe, idiosyncratic reaction to a drug characterized by a prolonged latency period. It is followed by a variety of clinical manifestations, usually fever, rash, lymphadenopathy, eosinophilia, and a wide range of mild-to-severe systemic presentations. Among sulfonamides, Dapsone, sulfamethoxazole-trimethoprim and sulfasalazine are the most common offending drugs. We report here a case of DRESS syndrome due to dapsone.

Keywords: Dapsone, Dapsone hypersensitivity syndrome, DRESS syndrome

INTRODUCTION

According to WHO, adverse drug reaction (ADR) is defined as any response to drug which is noxious or unintended and occurs at a dose normally used in man for prophylaxis, diagnosis or treatment of diseases or for modification of physiological function. ADRs may be said to be the inevitable price we pay for the benefits of modern drug therapy. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening disease with a mortality rate of around 10%. It is a severe hypersensitivity reaction to a medication or its reactive metabolites, which may be associated with enzymatic defects in drug metabolism. Aromatic anticonvulsants such as phenytoin, carbamazepine, and phenobarbital and sulfonamides such as dapsone and sulfasalazine are the most frequently reported drugs causing DRESS. We report here a case of DRESS syndrome due to dapsone.

CASE REPORT

A 40-year-old male patient presented with chief complaint of dark patches over right forearm. Initially they were small in size and gradually progressed to involve the both upper limbs, chest, back and lower limbs over the course of 2 days.

The patient consulted a local doctor who diagnosed it as lichen planus and was treated with dapsone 100 mg OD which patient took for 15 days. During the course of treatment, the patient developed fluid filled lesions on the lips, chest, abdomen, back, genitalia, upper and lower limbs. The lesions burst on application of pressure forming raw red areas in one day. The patient also complained of fever and throat pain.

Laboratory investigations included a total leukocyte count of 9500 cell/mm³ (3000-11000 cells/mm³), eosinophils 6.8% (2-3%), hemoglobin 10 g/dl (12-16 g/dl), total protein 4.6 g/dl (6-8 g/dl), albumin 1.5 g/dl (3.5-5 g/dl), bilirubin 0.2 mg/dl (0.1-1.2 mg/dl), AST - 26 U/l (upto 37 U/l), ALT 13 U/l (up to 40 U/l), alkaline phosphatase 91 U/l (40-170 U/l), urea 17 mg/dl (10-45 mg/dl) and creatinine - 0.6 mg/dl (0.5-1.5 mg/dl).
Diagnosis and management

Patient was diagnosed to have DRESS syndrome induced by dapsone. He was treated in our hospital with piperacillin-tazobactam, metronidazole, paracetamol, triamcinolone, dexamethasone, IV fluids, chlorhexidine mouth wash, saline compression and pantoprazole.

**DISCUSSION**

Dapsone Hypersensitivity Syndrome (DHS) is a rare dose-independent adverse effect reported with dapsone use in leprosy, malaria prophylaxis, dermatitis herpetiformis, lichen planus and various other conditions. DHS can develop several weeks to as long as six months after treatment initiation and the reported incidence ranges from 0.5% to 3%. Manifestations of DHS include high grade fever, skin rash, lymphadenopathy, eosinophilia, hepatitis, acute pneumonitis, neurological and other systemic features of multi-organ dysfunction. The drug hypersensitivity syndrome associated with Drug Rash, Eosinophilia and Systemic Symptoms, as noted in the present case, is called DRESS syndrome. Common pharmacologic triggers for DRESS include aromatic anticonvulsants (mainly phenobarbital, phenytoin, and carbamazepine), antibiotics (mainly trimethoprim-sulfamethoxazole, minocycline, vancomycin, and antitubercular drugs), dapsone, allopurinol and nevirapine. The aetiology of DRESS syndrome is not yet clear, but it has been suggested that this condition is multifactorial and may include an immune-mediated hypersensitivity component that is a direct effect of an interaction between the drugs or their metabolites and a genetic susceptibility. Furthermore, an interplay between drugs, viruses (mainly herpes virus 6 [HHV6], but also HHV7, Epstein-Barr virus and cytomegalovirus) and immune system may have a role as trigger of DRESS syndrome. Other clinical conditions, such as acute viral infections, hepatitis, sepsis, autoimmune disease, and haematologic disorders, should be considered in the differential diagnosis of DRESS syndrome.

The clinical manifestations are not immediate and usually appear 2 to 8 weeks after introduction of the triggering drug. Common features consist of fever, rash, lymphadenopathy, hematological findings (eosinophilia, leukocytosis, etc.), and abnormal liver function tests, which can mimic viral hepatitis. The cutaneous
manifestations typically consist of an urticarial, maculopapular eruption and, in some instances, vesicles, bullae, pustules, purpura, target lesions, facial edema, cheilitis, and erythroderma. Visceral involvement (hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis) is the major cause of morbidity and mortality in this syndrome. Many cases are associated with leukocytosis with eosinophilia (90%).

Various authors have reported varying incidences of DRESS syndrome with dapsone. This case was diagnosed by correlating clinical symptoms and regiSCAR criteria for DRESS syndrome. Simrun et al reported a case of DRESS syndrome due to dapsone. Causality analysis using Naranjo’s scale showed that phenytoin is the probable cause of the adverse reaction in present case (score=6).

DRESS syndrome is a life threatening condition and therefore supportive care is an essential part of the therapeutic approach. Prophylactic antibiotic use is recommended. The management involves prompt discontinuation of dapsone, systemic steroids (oral prednisolone 1 mg/kg per day or intravenous methylprednisolone in equivalent doses). Gradual tapering of prednisolone (over more than a month) is recommended considering the persistence of dapsone in the body up to 35 days. Mortality as high as 12-23% has been reported. Thus, a high index of suspicion for early diagnosis, along with prompt treatment are essential to prevent fatalities and late complication. In the present case however, the patient recovered well with the given treatment.

CONCLUSION

From this study it was concluded, knowledge of the past medical history of the patient regarding past drug allergy, family history of drug allergy or death in the family due to a drug is of great importance in order to avoid morbidity and mortality associated with hypersensitivity to the drug. It is of utmost importance to be vigilant while administering drugs known to cause DRESS syndrome. Early diagnosis, identification of the culprit drug, its prompt withdrawal and specialized supportive care is the key to the management of a case of DRESS syndrome. Since dapsone is one of the commonest drug to cause DRESS syndrome, its use needs to be reconsidered in view of safer alternatives available.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
